XML 13 R3.htm IDEA: XBRL DOCUMENT v3.22.1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
 3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Revenues:    
Total revenues $ 199,074 $ 371,120
Operating expenses:    
Research and development 55,978,611 39,044,418
General and administrative 15,953,458 13,881,194
Total operating expenses 71,932,069 52,925,612
Loss from operations (71,732,995) (52,554,492)
Other income (expense):    
Interest income 669,814 769,237
Interest expense (313,488) (513,034)
Loss on investment in affiliated entities (537,728) (830,475)
Net unrealized loss on available-for-sale equity securities (4,840,641) (847,958)
Other income (expense), net (153,468) 8,978
Net loss before share in net loss of Geneos (76,908,506) (53,967,744)
Share in net loss of Geneos (2,165,213) (434,387)
Net loss $ (79,073,719) $ (54,402,131)
Net loss per share    
Basic (in dollars per share) $ (0.36) $ (0.27)
Diluted (in dollars per share) $ (0.36) $ (0.27)
Weighted average number of common shares outstanding    
Basic (in shares) 218,940,693 202,414,445
Diluted (in shares) 218,940,693 202,414,445
Revenue under collaborative research and development arrangements    
Revenues:    
Total revenues $ 65,895 $ 39,615
Revenue under collaborative research and development arrangements with affiliated entities    
Revenues:    
Total revenues 8,842 49,949
Other revenue    
Revenues:    
Total revenues $ 124,337 $ 281,556